MINNETONKA, Minn., Aug. 15, 2011 /PRNewswire/ — Uroplasty, Inc.
(Nasdaq:
UPI), a medical device company that develops, manufactures and
markets innovative proprietary products to treat voiding
dysfunctions, today announced that the results of two clinical
studies using Uroplasty’s Urgent® PC Neuromodulation System are
scheduled to be presented at the International Continence Society
meeting, August 29-September 2, 2011 in Glasgow, Scotland.
“These data from on-going clinical studies continue to
demonstrate the long-term efficacy of percutaneous tibial nerve
stimulation (PTNS) delivered via Urgent PC in the treatment of
overactive bladder syndrome,” said David Kaysen, President and CEO
of Uroplasty. “The studies build on a growing body of
evidence that validates the treatment protocol, usefulness with
both young and elderly patients, and the durability of the
improvements with continued PTNS therapy.”
ICS Presentations
SUmiT Trial Outcomes: Clinical Insights into Percutaneous Tibial
Nerve Stimulation, presented by Dr. Peter Sand, NorthShore
University Health, Chicago, IL Demonstrated that results are
consistent for patients regardless of age Demonstrated that
improvement occurs throughout the series of 12 initial treatments,
with more improvement occurring during treatments 7 through
12Treatment Interval Frequency of Percutaneous Tibial Nerve
Stimulation: 18-Month Results from the STEP Study, presented by
Dr. Kenneth Peters, William Beaumont Hospital, Royal Oak, MI
Responders to the initial series of 12 treatments treated with
regular PTNS therapy, on an average of once per month, sustained
their improvements in voiding symptoms and Quality of Life measures
throughout 18 months of therapy
About Uroplasty Uroplasty, Inc., headquartered in Minnetonka,
Minnesota,
‘/>”/>
